Dive in
We have our own point of view on the people, technologies, and conversations that will shape the future.
Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.
Delfi Diagnostics has developed a test that combines ultra-low-cost sequencing and machine learning to detect cancer early.
Recursion is a breakthrough drug discovery company that combines a novel computer vision platform with deep disease biology and chemistry.
Ophelia is reinventing addiction treatment and dramatically improving access to best-in-class care with telemedicine.
In the face of a national emergency in child and adolescent mental health, urgent measures are needed to help those in need.
Attention Digital Health Founders: We are now accepting applications to attend the Digital Health Founder’s Fellowship
Riva’s mission is to improve cardiovascular disease worldwide using just the smartphones that people already have in their pockets, replacing 130-year-old blood pressure cuff technology.
Opioid use disorder (OUD) is an epidemic that will define our generation. Roughly 90 million Americans use opioids and over 10 million misuse them.
We believe purpose-built vertical SaaS will help make drug discovery more effective and efficient and ultimately improve healthcare outcomes.
At Menlo, we believe the pace of innovation in new medicines will continue to accelerate, powered by the combination of advances in biology, advances in information technology, and even the lasting implications of the global pandemic.
Here at Menlo, we are building an investing practice focused on three of the most exciting areas of healthcare: therapeutic platforms, digital health, and transformative technologies.
Nearly half of U.S. adults—108 million people—have high blood pressure, which is the #1 controllable risk for both heart disease and stroke, the two leading worldwide causes of death.
H1 is a unique healthcare data SaaS company with proprietary data, compelling initial applications, and potential to expand.
The pandemic’s pressures compressed trends toward digital and virtual care that might otherwise have taken years into a few months.
Congratulations to Bernard Coulie and the team at Pliant Therapeutics on a successful IPO!
In order to fulfill the promise of improving healthcare outcomes, electronic medical records (EMRs) must be both portable and private.
